Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-03-13

FDA Approved: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE — Supplemental Application (Jubilant Cadista Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved Jubilant Cadista Pharmaceuticals' supplemental application for Losartan Potassium and Hydrochlorothiazide, a generic combination antihypertensive p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Losartan potassium and hydrochlorothiazide (losartan potassium and hydrochlorothiazide)

Snippet

SUPPL AP for LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE)